Expansion/validation cohort (for feasibility/external relevance)Adults with other CAR-T indications (e.g., B-ALL receiving CD19 CAR-T or multiple myeloma receiving BCMA CAR-T) under identical sampling and lab procedures; used for external validation and, if numbers permit, secondary pooled analyses. This evidence concerns the gene CD19 and plasma cell myeloma.